Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-07-12
2011-07-12
Blanchard, David J. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S388100, C424S133100, C424S141100, C424S145100, C424S179100
Reexamination Certificate
active
07977464
ABSTRACT:
There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human TNFα. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by TNFα.
REFERENCES:
patent: 5919452 (1999-07-01), Le et al.
patent: 6350860 (2002-02-01), Buyse et al.
patent: 7012135 (2006-03-01), Athwal et al.
patent: 0 239 400 (1987-09-01), None
patent: 0 392 745 (1990-10-01), None
patent: 2 297 145 (1996-07-01), None
patent: WO 86/01533 (1986-03-01), None
patent: WO 89/00195 (1989-01-01), None
patent: WO 89/01476 (1989-02-01), None
patent: WO 90/07861 (1990-07-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO 92/11383 (1992-07-01), None
patent: WO 92/22583 (1992-12-01), None
patent: WO 93/06231 (1993-04-01), None
patent: WO 96/33204 (1996-10-01), None
patent: WO 97/29131 (1997-08-01), None
patent: WO 98/20734 (1998-05-01), None
patent: WO 98/25971 (1998-06-01), None
patent: WO 99/09055 (1999-02-01), None
patent: WO 99/15549 (1999-04-01), None
patent: WO 99/45964 (1999-09-01), None
patent: WO 9964460 (1999-12-01), None
Adorini, L. and Sinigaglia, F., “Pathogenesis and immunotherapy of autoimmune diseases,”Trends in Immunology Today, 18(5):209-211, (1997).
Arnett, F.C., et al., “The American Rheumatism Association 1987 Revised Criteria for the Classification of Rheumatoid Arthritis,”Arthritis and Rheumatism, 31(3):315-324, (Mar. 1988).
Ausubel (Ed.), Current Protocols in Molecular Biology, Wiley, NY (1999).
Beutler, et al., “Shock and tissue injury induced by recombinant human cachetin,”Science, 234:470-474, (1985).
Bodmer, M, et al., “Preclinical review of anti-tumor necrosis factor monoclonal antibodies,”Critical Care Medicine, 21(10):S441-S446, (1993).
Boers, M., et al., “World Health Organization and International League of Associations for Rheumatology Core Endpoints for Symptom Modifying Antirheumatic Drugs in Rheumatoid Arthritis Clinical Trials,”The Journal of Rheumatology, (Supplement 41), 21:86-89, (1994).
Chapman, A.P., “Therapeutic antibody fragments with prolonged in vivo half-lives,”Nature Biotechnology, 17:780-783, (Aug. 1999).
Crameri, A., et al., “DNA shuffling of a family of genes from diverse species accelerates directed evolution,”Nature, 391(6664):288-291, (Jan. 1988).
Elliott, M.J., et al., “Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis,”The Lancet, 344:1105-1110, (Oct. 22, 1994).
Feldman, M., et al., “Anti-TNFα Therapy Is Useful in rheumatoid Arthritis and Crohn's Disease: Analysis of the Mechanism of Action Predicts Utility in Other Diseases,”Transplantation Proceedings, 30:4126-4127, (1998).
Feldmann, M., et al., “Anti-Tumor Necrosis Factor-α Therapy of Rheumatoid Arthritis,”Advances in Immunology, 64:283-350, (1997).
Felson, D.T., “American College of Rheumatology Preliminary Definition of Improvement in Rheumatoid Arthritis,”Arthritis and Rheumatism, 38(6):727-735, (Jun. 1995).
Fendly, B.M., et al., “Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor,”Hybridoma, 6(4):359-370, (1987).
Flanagan, J.G. and Rabbitts, T.H., “Arrangement of human immunoglobulin heavy chain constant region genes implies evolutionary duplication of a segment containing γ, ε and α genes,”Nature, 300(5894):709-713, (Dec. 1982).
Genebank Accession No. J00241, version J00241.1 Gl:185938, “Human Ig germline kappa-L chain, C region (inv3 allele),” accessed by PTO on Apr. 6, 2002, (Jan. 5, 1995).
Hieter, P.A., et al., “Cloned Human and Mouse Kappa Immunoglobulin Constant and J Region Genes Conserve Homology in Functional Segments,”Cell, 22(Part 1):197-207, (Nov. 1980).
Keffer, J., et al., “Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis,”The EMBO Journal, 10(13):4025-4031, (1991).
Kirschenbaum, L., et al., “Antibodies to TNF-α: Too little, too late?,”Critical Care Medicine, 26(10):1625-1626, (1998).
Low, N.M., et al., “Mimicking Somatic Hypermutation: Affinity Maturation of Antibodies Displayed on Bacteriophage Using a Bacterial Mutator Strain,”J. Mol. Biol., 260:359-368, (1996).
Maini, R.N., et al., “Clinical Response of Rheumatoid Arthritis (RA) to Anti-TNFα (cA2) Monoclonal Antibody (mab) is Related to Administered Dose and Persistence of Circulating Antibody,”Arthritis Rheum., 38(9) (Supplement):S186, (1995).
Maini, R., et al., “Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial,”The Lancet, 354:1932-1939, (Dec. 4, 1999).
Marks, J.D., et al., “By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling,” Bio/Technology, 10:779-783, (Jul. 1992).
McKown, K.M., et al., “Lack of Efficacy of Oral Bovine Type II Collagen Added to Existing Therapy in Rheumatoid Arthritis,”Cancer Research, 60:3088-3095, (Jun. 2000).
Meager, A., et al., “Preparation and Characterization of Monoclonal Antibodies Directed Against Antigenic Determinants of Recombinant Human Tumour Necrosis Factor (rTNF),”Hybridoma, 6(3):305-311, (1987).
Monaco-Malbet, S., et al., “Mutual Conformational Adaptations in Antigen and Antibody upon Complex Formation between an Fab and HIV-1 Capsid Protein p24,”Structure, 8:1069-1077, (Oct. 2000).
Moreland, L.W., et al., “Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial,”Ann Intern Med., 130:478-486, (1999).
Patten, P.A., et al., “Applications of DNA shuffling to pharmaceuticals and vaccines,”Current Opinion in Biotechnology, 87:724-733, (1997).
Paul, W.E., “Structure and Function of Immunoglobulins,”Fundamental Immunology, 3rded., pp. 292-295, (1993).
Prevoo, M.L.L., “Modified Disease Activity Scores That Include Twenty-Eight-Joint Counts,”Arthritis and Rheumatism, 38(1):44-48, (Jan. 1995).
Rankin, E.C.C., et al., “The Therapeutic Effects of an Engineered Human Anti-Tumour Necrosis Factor Alpha Antibody (CDP571) in Rheumatoid Arthritis,”British Journal of Rheumatology, 34:334-342, (1995).
Riechmann, L., et al., “Reshaping human antibodies for therapy,”Nature, 332:323-327, (Mar. 1988).
Rudikoff, S., et al., “Single amino acid substitution altering antigen-binding specificity,”Proc. Natl. Acad. Sci. USA, 79:1979-1983, (Mar. 1982).
Scott, D.L., et al., “Disease activity in rheumatoid arthritis: preliminary report of the Consensus Study Group of the European Workshop for Rheumatology Research,”Clinical and Experimental Rheumatology, 10:521-525, (1992).
Shimamoto, Y., et al., “Monoclonal antibodies against human recombinant tumor necrosis factor: prevention of endotoxic shock,”Immunology Letters, 17:311-318, (1988).
Stephens, S., et al., “Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses,”Immunology, 85:668-674, (1995).
Thompson, J., et al., “Affinity Maturation of a High-affinity Human Monoclonal Antibody Against the Third Hypervariable Loop of Human Immunodeficiency Virus: Use of Phage Display to Improve Affinity and Broaden Strain Reactivity,”J. Mol. Biol., 256:77-88, (1996).
Vaughan, T., et al., “Human antibodies by design,”Nature Biotechnology, 16:535-539, (Jun. 1998).
Verhoeyen, M., et al, “Reshaping Human Antibodies: Grafting an Antily
Athwal Diljeet Singh
Brown Derek Thomas
Chapman Andrew Paul
King David John
Popplewell Andrew George
Blanchard David J.
O'Connor Cozen
UCB Pharma S.A.
LandOfFree
Antibody molecules specific to human tumour necrosis factor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibody molecules specific to human tumour necrosis factor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody molecules specific to human tumour necrosis factor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2720048